You are here: Industry Insights > eosinophilic asthma

News List

AZ’s Fasenra study confirms robust efficacy in eosinophilic asthma pharmatimes
August 11, 2020
AstraZeneca has revealed positive results from a Phase IIIb trial of Fasenra (benralizumab) in severe eosinophilic asthma patients.
Nucala by GSK receives EU approval for patients with severe eosinophilic asthma biospectrumasia
August 04, 2019
96% of patients in studies preferred self-administration at home over being treated in clinic
AZ’ Fasenra shows long-term efficacy in eosinophilic asthma pharmatimes
September 20, 2018
AstraZeneca has unveiled data from a Phase III extension trial highlighting the efficacy of biologic Fasenra as an add-on maintenance treatment...
NICE backs AZ’ asthma biologic Fasenra pharmatimes
July 17, 2018
AstraZeneca’s biologic Fasenra will likely be funded on the NHS as a treatment for people with severe eosinophilic asthma.
AZ's Fasenra approved in Europe as an add-on for severe eosinophilic asthma pharmafile
January 12, 2018
AstraZeneca and its Biologics R & D division, MedImmune, announced that their drug, Fasenra (benralizumab), has been approved by the European Commission (EC)
NICE recommends Teva’s Cinqaero to treat severe eosinophilic asthma pharmaceutical-technology
July 24, 2017
The UK National Institute for Health and Care Excellence (NICE) has recommended Teva Pharmaceutical Industries’ Cinqaero (reslizumab) for the treatment of patients with severe eosinophilic asthma.